<DOC>
	<DOCNO>NCT01561950</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial evaluate effectiveness activate recombinant human factor VII mitigate experimentally-induced bleeding healthy volunteer treat clopidogrel ( PlavixÂ® ) .</brief_summary>
	<brief_title>Efficacy Activated Recombinant Human Factor VII Healthy Volunteers Treated Punch Biopsy Mediated Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>PT/PTT within normal laboratory range ( e.g. , PT : 9.412.0 ) Platelet count within normal laboratory range The receipt investigational drug within 1 month prior trial Use anticoagulation therapydefined vitamin K antagonist , platelet antagonist , heparin ( low molecular weight heparin ) , aspirin NSAIDs ( nonsteroidal antiinflammatory drug ) within 30 day prior trial AfricanAmerican race Weight equal 160 kg</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>